Author: Leslie Gibson McCarthy

A new study by the School of Medicine, published Dec. 22 in Nature Communications, helps explain why development of a better vaccine for tuberculosis has been stymied.

Scientists at the School of Medicine have detailed the structure of a molecule that has been implicated in Alzheimer’s disease. Knowing the shape of the molecule — and how that shape may be disrupted by certain genetic mutations — can help in understanding how Alzheimer’s and other neurodegenerative diseases develop and how to prevent and treat them.

Measuring brain waves, Washington University researchers have found that clinically depressed children don’t respond to rewards the way other children do. The findings may show how the brain processes emotions in young children with depression.

While a particular metabolic pathway shows potential to slow down the aging process, new research indicates a downside: That same pathway may drive brain cancer. The pathway, known as the nicotinamide adenine dinucleotide (NAD+) pathway, is overactive in a deadly form of brain cancer known as glioblastoma, according to a study by researchers at Washington University School of Medicine in St. Louis.

Researchers at Washington University School of Medicine in St. Louis are launching a study aimed at identifying effective treatment methods for seniors with depression that does not respond to standard medications.

Henry Schvey is a steadfast presence in the Performing Arts Department in Arts & Sciences at Washington University in St. Louis, having directed more than 25 plays in his nearly 30-year tenure, in addition to teaching and writing. Now, a new memoir is adding to his body of work in the place he calls home.

Patients with the most lethal form of acute myeloid leukemia (AML) – based on genetic profiles of their cancers – typically survive for only four to six months after diagnosis, even with aggressive chemotherapy. But new research led by the School of Medicine indicates that such patients, paradoxically, may live longer if they receive a milder chemotherapy drug.

The parasite that causes river blindness infects about 37 million people in parts of Africa and Latin America, causing blindness and other major eye and skin diseases in about 5 million of them. A study from the School of Medicine sheds light on the genetic makeup of the parasite, a step toward the goal of eradication.

A combination of two topical drugs that have been in use for years triggers a robust immune response against precancerous skin lesions, according to a new study. The research, from the School of Medicine and Harvard Medical School, shows that the therapy activates the immune system’s T cells, which then attack the abnormal skin cells. The study was published Nov. 21 in The Journal of Clinical Investigation.

Three School of Medicine faculty members are among 391 new fellows selected by the American Association for the Advancement of Science (AAAS), the world’s largest general scientific society. Azad Bonni, Phyllis I. Hanson and Gary D. Stormo will receive the highest honor awarded by AAAS.